Healthcare >> CEO Interviews >> January 13, 2000
DAVID V. GOEDDEL, PH.D. is a founder of Tularik and has been a director
of the Company since its inception. Dr. Goeddel has served as CEO of the
Company since April 1996 and as President from April 1996 to December
1997. Dr. Goeddel joined Tularik as Vice President of Research in 1993.
From 1978 to 1993, Dr. Goeddel was with Genentech. The first scientist
hired at Genentech, Dr., Goeddel most recently held the positions of
Genentech Fellow, Staff Scientist and Director of Molecular Biology.
His pioneering work in the field of gene cloning and expression research
has been the basis for five important marketed therapeutics developed
by Genentech, including human insulin, human growth hormone, interferon-
a, interferon-g and tPA. Due to his significant contributions in this
field, Dr. Goeddel has been elected as a member of the National Academy
of Sciences and the American Academy of Arts and Sciences. Dr., Goeddel
has edited two textbooks, published more than 200 scientific papers and
received many awards, including the Eli Lilly Award in Biological
Chemistry and The Scheele Medal. Dr., Goeddel received his Ph.D. in
Biochemistry from the University of Colorado in 1977 and subsequently
performed postdoctoral research at Stanford Research Institute. Profile
the company, just to set the stage for the readers?
Mr. Goeddel: Tularik is eight years old. We were founded by myself
